Secondary
Bellicum Pharmaceuticals
We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders.
Symbol
BLCM
Final Price
$8.97
Anticipated Date
TBD
Underwriters
Citigroup, Jefferies, Guggenheim, Ladenburg Thalman, Raymond James
To view the prospectus for Bellicum Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277